PRRX1 Is a Novel Prognostic Biomarker and Facilitates Tumor Progression Through Epithelial–Mesenchymal Transition in Uveal Melanoma

• DOI: 10.3389/fimmu.2022.754645
• Publication Date: 2022-02-25T09:40:17Z
• Authors: Zhishang Meng; Yanzhu Chen; Wenyi Wu; Bin Yan; Lusi Zhang; Huihui Chen; Yongan Meng; Youling Liang; Xiaoxi Yao; Jing Luo
• Keywords: Homeodomain Proteins; Inflammation; Uveal Neoplasms; 0303 health sciences; Epithelial-Mesenchymal Transition; Immunology; RC581-607; epithelial–mesenchymal transition; Prognosis; 3. Good health; 03 medical and health sciences; Tumor Microenvironment; tumor microenvironment; biomarker; Humans; uveal melanoma; Immunologic diseases. Allergy; PRRX1; Melanoma

Uveal melanoma (UM) is the most common primary intraocular malignancy in adults. UM develops and sustained by inflammation immunosuppression from tumor microenvironment (TME). This study sought to identify a reliable TME-related biomarker that could provide survival prediction new insight into therapy for patients. Based on clinical characteristics RNA-seq transcriptome data of 80 samples The Cancer Genome Atlas (TCGA) database, PRRX1 as TME- prognosis-related gene was identified using ESTIMATE algorithm LASSO–Cox regression model. A prognostic model based constructed validated with Gene Expression Omnibus (GEO) dataset 63 samples. High expression associated poorer overall (OS) metastasis-free (MFS) Comprehensive results analysis showed an independent predictor UM. Then immunological demonstrated higher accompanied immune checkpoint genes, lower mutation burden (TMB), greater cell infiltration TME. set enrichment (GSEA) high correlated angiogenesis, epithelial–mesenchymal transition (EMT), inflammation. Furthermore, downregulation weakened process EMT, reduced invasion migration human line MuM-2B vitro . Taken together, these findings indicated increased independently factor OS MFS patients UM, promotes malignant progression facilitating suggesting may be potential target therapy.